The other study that demonstrated increased efficacy of monotherapy in high PD-L1 expressors was IMpower 110, which demonstrated a benefit of atezolizumab at a fixed dose of 1200 mg every 3 weeks versus platinum-based CT in patients with advanced NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.